91 results
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
payments thereunder, timing and results of nonclinical studies and clinical trials, efficacy and safety profiles of our products and product candidates … low-grade glioma. The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
TM
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
12 Jun 24
Regulation FD Disclosure
8:07am
and clinical trials, efficacy and safety profiles of our products and product candidates, the ability of tovorafenib to treat pediatric low-grade glioma (pLGG … VRK1. pLGG, pediatric low-grade glioma. 4 The safety and efficacy of investigational agents and/or investigational uses of approved products have
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
and clinical trials, efficacy and safety profiles of our products and product candidates, the ability of tovorafenib to treat pediatric low-grade glioma (pLGG … . pLGG, pediatric low-grade glioma. 4 The safety and efficacy of investigational agents and/or investigational uses of approved products have not been
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
as designed, any expectations about safety, efficacy, timing and ability to complete clinical trials, release data results and to obtain regulatory
8-K
EX-99.2
5uhih7rw85d84n
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
8-K
0m6w0p
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
8s2zgag
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
byj4xfuq1
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
c67zctspn91omy
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
xs6g113rmikfi
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
tw6lkhi 386
17 Jan 24
Day One Announces Two New Appointments to Board of Directors
8:25am
8-K
EX-99.2
t3bbcmxfibiml4
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
shc36d4j0i3s4ciq
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-14.1
9cqautw1op69a
8 Dec 23
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:05pm
8-K
EX-99.1
w76n4n7fyeylyqqjiba
17 Nov 23
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
7:07am
8-K
EX-99.2
bo8sjk5 0q46a
17 Nov 23
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
7:07am
8-K
EX-99.2
d1m70bd95y6x
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm